Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice
- 1 October 2007
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (10), 3737-3739
- https://doi.org/10.1128/aac.00730-07
Abstract
Eight weeks of treatment with rifampin-streptomycin sterilizes Mycobacterium ulcerans infection in mice. Because the bactericidal activity against M. ulcerans of the combination rifampin-moxifloxacin, rifampin-clarithromycin, or moxifloxacin-clarithromycin was similar to that of rifampin-streptomycin, these combinations might be considered as alternative, orally administered combined regimens for treatment of Buruli ulcer in humans.This publication has 5 references indexed in Scilit:
- Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer ( Mycobacterium ulcerans Disease)Antimicrobial Agents and Chemotherapy, 2007
- Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-AmikacinAntimicrobial Agents and Chemotherapy, 2007
- In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulceransAntimicrobial Agents and Chemotherapy, 2006
- Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in HumansAntimicrobial Agents and Chemotherapy, 2005
- Isolation of Three Mycobacterium ulcerans Strains Resistant to Rifampin after Experimental Chemotherapy of MiceAntimicrobial Agents and Chemotherapy, 2003